Fresubin Protein Energy Drink by Fresenius Kabi - ready-to-drink nutrition focus

Fresubin Protein Energy Drink sits cold in a hospital fridge, the plastic bottle slightly misted as a nurse twists the cap and the sweet vanilla smell briefly cuts through the disinfectant in the ward corridor. It is a compact meal, not a lifestyle drink. Dietitian Dr. Anna Keller reaches for it when a patient simply cannot manage a full plate but still needs calories and protein.

What Fresubin Protein Energy Drink offers

Fresubin Protein Energy Drink is an oral nutritional supplement from Fresenius Kabi aimed at patients with or at risk of disease-related malnutrition. Each 200 ml bottle typically provides about 300 kcal, which corresponds to 1.5 kcal per millilitre, and a high share of energy from protein. The drink is designed to be taken in addition to normal meals, not as a casual refreshment.

The product is usually lactose-poor and gluten-free, which makes it suitable for most patients on standard hospital diets, including those with mild intolerances. Fresenius Kabi offers several flavours such as vanilla, chocolate and fruit varieties to reduce taste fatigue during longer therapies. These details are clearly laid out in the official product information for healthcare professionals.

Target group and typical use cases

Fresenius Kabi positions Fresubin Protein Energy Drink for adults who cannot cover their nutritional requirements through regular food intake alone, for example after major surgery, during cancer therapy or in chronic illnesses that reduce appetite. Doctors and dietitians prescribe or recommend the drink when weight loss, reduced muscle mass or poor lab values indicate a relevant nutritional risk.

In practice, the drink often appears on trays in oncology or geriatric wards, where small bottles are easier to finish than full meals. Patients are usually advised to drink Fresubin slowly, between main meals, and to chill the bottle because lower temperature can make the texture and taste more pleasant. Some clinicians also suggest sipping it through a straw when nausea is an issue.

Formulation, packaging and flavours

According to the official Fresubin Protein Energy Drink data sheet from Fresenius Kabi, the drink delivers approximately 20 grams of protein per 200 ml bottle, depending on flavour. That is markedly more than a typical glass of milk and directly supports the maintenance of muscle mass in at-risk patients, especially when combined with physiotherapy.

The protein usually comes from milk-based sources, complemented by fats and carbohydrates to provide a balanced macronutrient profile tailored to clinical needs. The bottle size of around 200 ml is intentional: small enough to be manageable for frail patients, but large enough to deliver a meaningful energy and nutrient dose in a single serving.

Regulatory status and prescription practice

In many European markets, including Germany, Fresubin Protein Energy Drink is classified as a food for special medical purposes and therefore used under medical supervision. It is not marketed like a consumer fitness shake, but as part of medical nutrition therapy that follows defined guidelines, for example the recommendations of the European Society for Clinical Nutrition and Metabolism.

Physicians, dietitians and nursing staff coordinate the intake, often documenting exact volumes and flavours consumed. In long-term care facilities, dietitian teams such as the one led by nutrition specialist Dr. Keller routinely review whether a patient still needs the product or can step down to less intensive support as their condition improves.

Market segment and competition

Fresubin Protein Energy Drink competes in the clinical oral nutritional supplements segment, where global healthcare companies supply hospitals, rehabilitation clinics and homecare providers. Fresenius Kabi describes itself as a leading company in clinical nutrition and infusion therapy, and Fresubin is a central brand within this portfolio.

Other groups, including international nutrition specialists and pharmaceutical companies, offer comparable high-calorie, high-protein drinks. However, Fresubin has strong visibility in German-speaking markets, where Fresenius Kabi has a long history and an established distribution network. Formulation tweaks, flavour range and compatibility with specific disease patterns are important differentiators for decision-makers in clinics.

Production, quality control and sustainability

Fresenius Kabi operates manufacturing sites for clinical nutrition in Europe and other regions, applying pharmaceutical-grade quality systems to products such as Fresubin. Production is typically certified under relevant food safety and quality standards, which is essential when the target group includes immune-compromised patients.

The company has also communicated sustainability goals that extend to packaging and resource use in its nutrition plants. For Fresubin Protein Energy Drink, this mainly affects bottle materials, logistics and energy consumption in production. While the drink itself is a medical product, procurement teams in hospitals increasingly look at these environmental aspects when selecting suppliers.

How Fresubin fits into Fresenius Kabi’s strategy

Clinical nutrition is one of the core business areas of Fresenius Kabi, alongside intravenous drugs and medical devices. Management repeatedly highlights this segment as an important contributor to growth, driven by demographic trends such as aging populations and rising numbers of chronic disease patients who are at risk of malnutrition.

In recent corporate presentations, CEO Michael Sen and the Fresenius Kabi leadership have mentioned nutrition lines like Fresubin as part of the stable, cash-generating base business. Compared with more cyclical areas, demand for disease-related nutrition tends to be relatively steady, because it closely follows hospital and homecare patient volumes.

Digital support and information for professionals

Fresenius Kabi bundles information on Fresubin Protein Energy Drink and related products on its dedicated Fresubin websites, where healthcare professionals can access product specifications, usage recommendations and educational material. Many markets provide detailed nutrient tables, energy distributions and guidance on how to integrate the drink into broader nutritional plans.

Some local Fresenius Kabi teams additionally offer calculators and therapy support tools that help dietitians estimate requirements and select appropriate Fresubin products. These digital offerings are not a direct revenue source but help embed the brand into day-to-day clinical routines, from hospital wards to outpatient dietetic centers.

Homecare and reimbursement aspects

While hospital use is prominent, Fresubin Protein Energy Drink also plays a role in homecare settings, where patients continue nutrition therapy after discharge. Homecare providers often deliver regular shipments of bottles to patients, sometimes combined with nursing visits and monitoring of weight and intake.

In Germany and several other countries, health insurers reimburse oral nutritional supplements under defined conditions when prescribed by a physician. That means Fresubin sales volumes are closely linked to reimbursement policies and guidelines, which investors track because regulatory changes can influence demand patterns over time.

Financial context and Fresenius stock

For Fresenius SE & Co. KGaA, the Fresubin line, including Fresubin Protein Energy Drink, is part of the broader clinical nutrition business that contributes to Fresenius Kabi’s revenue and margin profile. In investor materials, the group points to stable growth in this segment, supported by demographic trends and increasing awareness of disease-related malnutrition as an independent risk factor.

On Xetra, the Fresenius SE & Co. KGaA share trades in euro under ISIN DE0005785604, and the performance of its clinical nutrition segment, with products like Fresubin Protein Energy Drink, forms one component of how analysts and investors assess the company.